Not financial advice. I am not a licensed investment advisor. This is independent research and personal opinion only. Early-stage biotech is high risk, and you could lose all of your investment. Please read the full disclosure and terms before making any decisions.
I spent 24 years running a financial services company I started at my kitchen table in Carmel Valley, San Diego, when I was 28 years old.
Twenty-four years.
I worked hard. I stayed disciplined. I saved. I built something real.
And somewhere along the way, I looked up and asked myself a deeper question:
What actually matters?
Money matters. It gives you options. It creates freedom. It can protect your family.
But money is still a tool.
What is the point of building wealth if your energy is gone, your body is breaking down, or you do not have enough healthy years left to enjoy the life you worked so hard to create?
That question changed everything for me.
What genuinely excites me now is this:
I believe we are living through a period where longevity science is becoming real in a way most people still do not fully see. Not just ideas. Not just hype. Real companies. Real mechanisms. Real data. Real clinical work. Real attempts to target the biology of aging and age-related decline.
That does not mean it is easy. It does not mean it is proven. It definitely does not mean most of these companies will succeed.
But it does mean this is worth paying attention to.
So I asked myself:
Why not do everything I can to help myself and the people I love live longer, healthier lives and also look for investment opportunities in the same space?
That is Everlife Capital.
What I Look For
I focus on early-stage longevity biotech, especially private companies and microcap public companies.
These are usually the companies most people ignore because they look too small, too early, too complicated, or too strange.
That is often where the opportunity is.
Here is the simple mental model I use:
If a small longevity biotech is working on something like arterial plaque reversal, mitochondrial function, immune rejuvenation, or another meaningful aging mechanism, and the science actually works, the upside may not be linear.
A company that looks tiny today may become something far bigger if it solves a real problem in a real way.
And beyond the financial upside, there is another kind of return that matters to me even more:
More healthy years.
More time with the people you love.
More energy to live your life.
That is what I mean by dual return:
Return on investment and return on life.
I have not found another sector that offers that combination in the same way.
I Learned This the Hard Way
When I first entered this space, I made the mistake a lot of people make.
I got excited.
I liked the story.
I trusted the pitch.
Then a few months later, I got the email that the company was being liquidated.
That was painful, and honestly, it was a great lesson.
After 24 years in business, I already knew that process beats emotion over the long run. I knew that in my bones.
So instead of investing based on excitement, I built a framework.
I call it the 21-Gate Framework.
It is a structured research checklist I use to evaluate longevity biotech companies before they earn a place in my tracked model portfolio.
Each gate is designed to catch a specific way these companies fail.
Not hypothetical failures.
Real ones.
I am talking about companies with elite scientists.
Companies with world-class names on the board.
Companies that raised serious money.
Companies that looked incredible on paper.
And still failed.
In many cases, the warning signs were visible before the collapse if you knew where to look.
That is what this framework is for.
A high score does not mean anyone should buy a stock.
It means I believe the company is worth deeper research.
That is very different.
I do the legwork. I show my work. You make your own decisions.
The 21-Gate Framework: What It Covers
Here is the honest version of how I think about the 21 gates. They are grouped into four areas.
The Team (Gates 1 to 2)
Good science can still fail with the wrong team.
I care about scientific credibility, but I also care about execution. I look for people who can actually build, finance, operate, and move a company forward.
A brilliant scientist without operator experience may still be valuable, but I do not treat credentials alone as enough.
The Science (Gates 3 to 8)
This is where I ask:
Does the mechanism make sense?
Can I trace the path from target to real-world clinical relevance?
Is there evidence beyond one exciting slide deck?
I look for clarity, translational logic, and evidence that connects the biology to meaningful outcomes.
I am especially careful about the difference between an age-related disease story and a true aging biology thesis. That distinction matters a lot.
The Business (Gates 9 to 16)
Great science fails for business reasons all the time.
This is where many investors stop looking, and where I spend a lot of time.
I evaluate things like capital structure, intellectual property, regulatory path, manufacturing practicality, reimbursement risk, market competition, and whether there is a realistic path to adoption if the product works.
A company can have promising science and still be a poor investment if the business is weak.
The Discipline (Gates 17 to 21)
This is the section that keeps me grounded.
It is easy to fall in love with a story in biotech. Discipline protects capital.
I want to see real milestones, credible de-risking paths, and clear thinking about what success and failure look like before more money gets spent.
I also care deeply about whether leadership can define what would make them stop.
A company that cannot say what failure would look like is often a company that keeps spending until there is nothing left.
What the Full Analysis Looks Like
Each gate has a scoring rubric from 1 to 5 with defined criteria.
Some gates also include veto thresholds. In plain English, that means there are certain weaknesses that cannot be saved by a high score somewhere else.
Why?
Because some gaps are just too dangerous to ignore.
For example, if the team cannot execute, if the regulatory path is unclear, or if the risk map is vague and generic, I want that to show up clearly in the analysis.
For paid subscribers, I share the deeper parts of the framework, including the scoring logic I use, veto thresholds, position sizing approach, and the way I think about healthspan impact in the context of investment research.
I am not publishing the full rubric publicly, because that is part of the value of the newsletter.
But I will always tell you what I found, what I like, what I do not like, and where I think the real risks are.
What I Publish
Each month, I publish 2 to 4 deep-dive research write-ups on early-stage private or microcap longevity biotech companies that I believe are worth serious analysis.
For companies already on my watchlist, I publish follow-up coverage as the science, financing, or business story evolves.
I publish scores.
I explain vetoes.
I show my reasoning.
And when the framework misses, because no framework is perfect, I will tell you where it missed and what I learned.
That matters to me.
I am not trying to build a hype machine.
I am building a disciplined research process in a field that could become one of the most important investment and human health opportunities of our lifetime.
If you are 45 plus, successful, busy, and starting to think more seriously about healthspan, longevity, and where to place your attention and capital, this newsletter was built for you.
Thanks for subscribing and joining the movement. here.
Eric Pemper
Everlife Capital